Literature DB >> 6368248

Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1).

N Hogg, G D Ross, D B Jones, M Slusarenko, M J Walport, P J Lachmann.   

Abstract

A monoclonal antibody (E11) was produced by immunization of mice with intact human cells of monocyte lineage. Despite the finding that E11 did not inhibit rosettes with C3b-coated sheep erythrocytes (EC3b), several lines of evidence indicated that E11 was specific for complement receptor type one (CR1). All monocytes, neutrophils, lymphocytes and erythrocytes that reacted with E11 formed EC3b rosettes. The E11 antigen on these cells was shown to be a molecule of 222 +/- 10 kDa. Treatment of lymphocytes, monocytes, and neutrophils with E11 followed by fluorescein-coupled F(ab')2 anti-mouse-IgG at 37 degrees C in buffer lacking sodium azide, led to capping or apparent endocytosis of the E11 antigen and a diminution in CR1 activity of 88%, 59% and 25%, respectively. This same treatment had no detectable effect on monocyte or neutrophil CR3 activity (EC3bi rosettes). Furthermore, with E11-capped lymphocytes, the residual EC3b rosetting was capped directly over the E11-fluorescence cap, whereas EC3d,g rosetting (CR2 specific) was undiminished and distributed evenly around the circumference of cells containing E11-fluorescence caps. Finally, the binding of E11 to cells was inhibited by the prior treatment of these cells with a well characterized rabbit polyclonal anti-CR1. These data indicated that E11 was specific for a site in CR1 that was distal from the C3b-binding site, so that E11 was unable to block CR1 activity. E11 proved to be useful for identifying CR1 on various cells in tissue sections, and for quantitating CR1 on erythrocytes and neutrophils. Erythrocytes and neutrophils from normal individuals were found to bind an average of 610 and 4.6 X 10(4) 125I-labeled E11 molecules per cell. When E11 was visualized in tissues by immunoperoxidase staining, the cells that apparently contained the greatest amounts of CR1 were dendritic reticulum cells and kidney podocytes. The E11 reactive dentritic reticulum cells were characteristic of both follicular and diffuse follicular center cell tumors. Lymphocytes from patients with chronic lymphocytic leukemia (CLL) characteristically expressed little E11, confirming earlier studies that CLL cells lacked CR1 activity detected by EAC1-3b rosette formation. Because normal B cells have been shown to express CR1 at a very early stage of maturation, the absence of CR1 on CLL cells is discordant with the immature nature of CLL cells defined by immunoglobulin expression.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6368248     DOI: 10.1002/eji.1830140307

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  44 in total

1.  Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.

Authors:  J A Tooze; D H Bevan
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

2.  Functional and molecular characterization by the CB04 monoclonal antibody of a cell surface structure exerting C3-complement receptor activity.

Authors:  F Malavasi; A Funaro; G Bellone; F Caligaris-Cappio; E Berti; C Tetta; P Dellabona; S DeMaria; M Campogrande; A P Cappa
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

3.  Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.

Authors:  H Shoham-Kessary; Y Naot; H Gershon
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

4.  Macrophage heterogeneity in human fetal tissue. Fetal macrophages.

Authors:  A M Oliver
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

5.  Application of a novel immunization protocol to the production of monoclonal antibodies specific for macrophages in human placenta.

Authors:  A D Nash; S Uren; C S Hawes; W Boyle
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

6.  Antigenic relationship between the alpha-chain of C3, a leucocyte-surface antigen involved in the activation of phagocytic cells, and a 50,000 MW B-cell antigen.

Authors:  T F Schulz; H Scharfenberger; J D Lambris; P Rieber; G Riethmüller; M P Dierich
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

7.  Comparison of human monocytes isolated by elutriation and adherence suggests that heterogeneity may reflect a continuum of maturation/activation states.

Authors:  I Dransfield; D Corcoran; L J Partridge; N Hogg; D R Burton
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

8.  The anti-lipid A antibody HA-1A binds to rough gram-negative bacteria, fixes complement and facilitates binding to erythrocyte CR1 (CD35).

Authors:  M Tonoli; K A Davies; P J Norsworthy; J Cohen; M J Walport
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Morphological evidence that activated polymorphs circulate in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D A McCarthy; J Bernhagen; M J Taylor; A S Hamblin; I James; P W Thompson; J D Perry
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

10.  Heterogeneity of non-lymphoid cells expressing HLA-D region antigens in human fetal gut.

Authors:  J Spencer; T T MacDonald; P G Isaacson
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.